NCT/Study#

64007957MMY3001

A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (TecDara) versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants with Relapsed or Refractory Multiple Myeloma

A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (TecDara) versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd) or Daratumumab SC,
Bortezomib, and Dexamethasone (DVd) in Participants with Relapsed or Refractory Multiple Myeloma

DISEASE GROUP:
Multiple Myeloma
current phase:
Phase III
STUDY STATUS:
Active
Location:
Hackensack, NJ
For More information: